Merck KGaA (ETR:MRK)
115.40
-0.90 (-0.77%)
Jun 5, 2025, 5:38 PM CET
Merck KGaA Revenue
Merck KGaA had revenue of 5.28B EUR in the quarter ending March 31, 2025, with 3.13% growth. This brings the company's revenue in the last twelve months to 21.32B, up 2.38% year-over-year. In the year 2024, Merck KGaA had annual revenue of 21.16B with 0.78% growth.
Revenue (ttm)
21.32B
Revenue Growth
+2.38%
P/S Ratio
2.37
Revenue / Employee
340.49K
Employees
59,020
Market Cap
50.56B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 21.16B | 163.00M | 0.78% |
Dec 31, 2023 | 20.99B | -1.24B | -5.57% |
Dec 31, 2022 | 22.23B | 2.55B | 12.93% |
Dec 31, 2021 | 19.69B | 2.15B | 12.28% |
Dec 31, 2020 | 17.53B | 1.38B | 8.56% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.14B |
Fresenius SE & Co. KGaA | 22.13B |
Bayer Aktiengesellschaft | 46.58B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.44B |
Carl Zeiss Meditec AG | 2.17B |
Fielmann Group AG | 2.33B |
SCHOTT Pharma AG & Co. KGaA | 972.81M |
Merck KGaA News
- 12 hours ago - EQS-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 1 day ago - SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX - Wallstreet:Online
- 8 days ago - Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor - Benzinga
- 10 days ago - Merck Foundation Chairman and CEO Meet Nigeria First Lady to Underscore Their Long-Term Commitment to Transform Patient Care Landscape in the Country - Business Upturn
- 15 days ago - EMD Serono Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active Lupus Rash - Benzinga
- 20 days ago - Merck KGaA 2025 Q1 - Results - Earnings Call Presentation - Seeking Alpha
- 20 days ago - Merck KGaA (MKGAF) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Merck KGaA Non-GAAP EPS of €2.12, revenue of €5.28B; updates FY25 outlook - Seeking Alpha